The novel C+/+/Tia1−/− model is also suited for testing the efficacy of therapeutic compounds aimed at the treatment of SMA and possibly other genetic diseases impacted by aberrant SMN and/or TIA1 expression. This evidence concerns the gene SMN2 and hereditary disease.